Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of ...

Investors might want to bet on Travere Therapeutics (TVTX), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

If you’re staring at Travere Therapeutics stock right now, weighing whether this is the right time to buy, sell, or just keep watching, you’re definitely not alone. Lately, the market has been ...

Evercore ISI lowered the firm’s price target on Travere Therapeutics (TVTX) to $35 from $45 and keeps an Outperform rating on the shares. All eyes ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's ...

4 analysts have expressed a variety of opinions on Travere Therapeutics (NASDAQ:TVTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Travere Therapeutics faces challenges following disappointing data from its PROTECT trial in September 2023. The FDA granted accelerated approval for Travere's FILSPARI, but its continued approval is ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will ...